Core Insights - ABVC BioPharma, Inc. has received an additional $50,000 in licensing fees from AiBtl BioPharma, bringing the total to $346,000, which supports the confidence in ABVC's mission [1][2] - The payment is linked to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD), valued at $667 million [2] - ABVC is strategically positioned in growing markets, with the global MDD market projected to grow from $11.51 billion in 2022 to $14.96 billion by 2032, and the ADHD treatment market expected to increase from $15.23 billion in 2022 at a CAGR of 7.3% [3] Company Overview - ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development [3] - The company utilizes in-licensed technology from renowned research institutions, including Stanford University and Cedars-Sinai Medical Center, to conduct proof-of-concept trials through Phase II of clinical development [3]
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners